Last reviewed · How we verify
Vaxigrip®
Vaxigrip is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Vaxigrip is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Vaxigrip® |
|---|---|
| Also known as | Vaxigrip, intramuscular trivalent influenza vaccine |
| Sponsor | National University Hospital, Singapore |
| Drug class | Inactivated influenza vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from three or four seasonal strains, which trigger both humoral and cellular immune responses without causing infection. Upon vaccination, the body produces specific antibodies and memory immune cells that recognize and neutralize circulating influenza viruses, providing protection against seasonal flu infection and reducing disease severity.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Maternal Determinants of Immunity to Influenza (PHASE4)
- Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children (PHASE1, PHASE2)
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
- Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong (PHASE4)
- Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel (PHASE4)
- Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old (PHASE3)
- Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA (PHASE2)
- Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxigrip® CI brief — competitive landscape report
- Vaxigrip® updates RSS · CI watch RSS
- National University Hospital, Singapore portfolio CI